Published online May 29, 2020. doi: 10.5500/wjt.v10.i5.104
Peer-review started: February 24, 2020
First decision: April 25, 2020
Revised: April 30, 2020
Accepted: May 12, 2020
Article in press: May 12, 2020
Published online: May 29, 2020
Processing time: 95 Days and 1.7 Hours
Currently, CLAD is mainly classified into two clinical phenotypes, BOS and RAS. These mechanisms are not clear but considered to involve complex immune-mediated mechanisms such as innate immunity, cellular immunity, humoral immunity and autoimmunity. Finally, tissue remodeling takes place, resulting in irreversible fibrosis. An apparent histological difference between BOS and RAS is the anatomical locations involved: namely, BOS mainly involves small airways while peripheral lung tissue remains relatively intact, while RAS involves multiple anatomical compartments including airways, pleura, interlobular septum, alveoli, and vasculature. Such difference in the distribution of fibrosis may be associated with different magnitude and quality of immune mechanisms including lymphoid neogenesis.
